Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo
in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST)
after complete surgery and with high risk of recurrence.